{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:28:23Z","timestamp":1773790103477,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10120-025-01705-8","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:53:38Z","timestamp":1768971218000},"page":"387-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902)"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-4156","authenticated-orcid":false,"given":"Shunji","family":"Endo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Miyagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Masuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Katsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyoshi","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Tsujinaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"1705_CR1","first-page":"159","volume":"15","author":"M Sasako","year":"1992","unstructured":"Sasako M, Maruyama K, Kinoshita T. Neoadjuvant chemotherapy for gastric cancer: indication and trial setting (in Japanese). Shokakigeka. 1992;15:159\u201367.","journal-title":"Shokakigeka"},{"key":"1705_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","volume":"24","author":"Y Iwasaki","year":"2021","unstructured":"Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24:492\u2013502.","journal-title":"Gastric Cancer"},{"key":"1705_CR3","doi-asserted-by":"publisher","first-page":"1697708","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17:1697708.","journal-title":"Lancet Oncol"},{"key":"1705_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00280-013-2257-z","volume":"72","author":"I Park","year":"2013","unstructured":"Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, Park YS, et al. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2013;72:815\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1705_CR5","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.23.02167","volume":"42","author":"YK Kang","year":"2024","unstructured":"Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III prodigy. J Clin Oncol. 2024;42:2961\u20135.","journal-title":"J Clin Oncol"},{"key":"1705_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1186\/s12885-022-09890-w","volume":"22","author":"S Endo","year":"2022","unstructured":"Endo S, Terazawa T, Goto M, Tanaka R, Kato T, Fujitani K, et al. Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study. BMC Cancer. 2022;22:811.","journal-title":"BMC Cancer"},{"key":"1705_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s10120-025-01608-8","volume":"28","author":"R Tanaka","year":"2025","unstructured":"Tanaka R, Endo S, Yamaguchi T, Miyagaki H, Kawada J, Omori T, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902). Gastric Cancer. 2025;28:662\u201372.","journal-title":"Gastric Cancer"},{"key":"1705_CR8","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma.15th ed. (in Japanese) Tokyo: Kanehara; 2017."},{"key":"1705_CR9","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines, 5th ed. (in Japanese) Tokyo: Kanehara; 2018."},{"key":"1705_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1705_CR11","unstructured":"Japan Clinical Oncology Group. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017. https:\/\/jcog.jp\/doctor\/tool\/ctcaev5\/ Accessed 24 Sep 2025"},{"key":"1705_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"1705_CR13","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients (in Japanese with an English abstract). Nippon Geka Gakkai Zasshi. 1984;85:1001\u20135.","journal-title":"Nippon Geka Gakkai Zasshi"},{"key":"1705_CR14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296\u2013304.","journal-title":"J Clin Oncol"},{"key":"1705_CR15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10120-023-01419-9","volume":"26","author":"Y Kodera","year":"2023","unstructured":"Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, et al. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in stage III gastric cancer: a final report of the JACCRO GC-07 study. Gastric Cancer. 2023;26:1063\u20138.","journal-title":"Gastric Cancer"},{"key":"1705_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10120-020-01137-6","volume":"24","author":"T Yamaguchi","year":"2021","unstructured":"Yamaguchi T, Takashima A, Nagashima K, Terashima M, Aizawa M, Ohashi M, et al. Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study. Gastric Cancer. 2021;24:701\u20139.","journal-title":"Gastric Cancer"},{"key":"1705_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ags3.12632","volume":"7","author":"Y Kurokawa","year":"2022","unstructured":"Kurokawa Y, Kawase T, Takeno A, Furukawa H, Yoshioka R, Saito T, et al. Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma. Ann Gastroenterol Surg. 2022;7:247\u201354.","journal-title":"Ann Gastroenterol Surg"},{"key":"1705_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10120-023-01453-7","volume":"27","author":"Y Kurokawa","year":"2024","unstructured":"Kurokawa Y, Doki Y, Kitabayashi R, Yoshikawa T, Nomura T, Tsuji K, et al. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric Cancer. 2024;27:366\u201374.","journal-title":"Gastric Cancer"},{"key":"1705_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10120-015-0564-2","volume":"19","author":"T Voron","year":"2016","unstructured":"Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, et al. Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer. 2016;19:1027\u201340.","journal-title":"Gastric Cancer"},{"key":"1705_CR20","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.3748\/wjg.v21.i40.11428","volume":"21","author":"S Pernot","year":"2015","unstructured":"Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21:11428\u201338.","journal-title":"World J Gastroenterol"},{"key":"1705_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-014-0110-9","volume":"33","author":"B Hultman","year":"2014","unstructured":"Hultman B, Mahteme H, Sundbom M, Ljungman M, Larsson R, Nygren P. Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy. J Exp Clin Cancer Res. 2014;33:110.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01705-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01705-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01705-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:00:21Z","timestamp":1772550021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01705-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01705-8","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships, which may be considered potential competing interests: SE has received speaker honoraria from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb Co., MSD K.K., and Takata Pharmaceutical Co., Ltd. TO has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Medtronic Japan Co., Ltd., Johnson & Johnson K.K., Ono Pharmaceutical Co., Ltd., and Bristol Myers Squibb Co. NT has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bristol Myers Squibb Co., and AstraZeneca K.K. YK has received research funding and lecture fees from Taiho Pharmaceutical Co., Ltd outside the submitted work. TSa has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Daiichi Sankyo Co., Ltd., Bristol Myers Squibb Co., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., and MSD K.K.; and research grants or contracts from Shionogi & Co., Ltd., Prelude Therapeutics Inc., Janssen Pharmaceutical K.K., Daiichi Sankyo Co., Ltd., and Amgen K.K. All remaining authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}